ACADIA Pharmaceuticals
Yahoo Finance • 2 months ago
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
SAN DIEGO, August 07, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at 10:... Full story
Yahoo Finance • 2 months ago
Analysts Expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) To Breakeven Soon
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the developmen... Full story
Yahoo Finance • 5 months ago
ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...
Total Revenue: $205.8 million, up 74% from the first quarter of 2023. NUPLAZID Sales: $129.9 million, a 10% increase from the previous year. DAYBUE Sales: $75.9 million, marking its first full quarter since launch. Cash Position: Increased... Full story
Yahoo Finance • 8 months ago
10 Stocks Receiving a Massive Vote of Approval From Wall Street Analysts
In this article, we will take a look at the 10 stocks receiving a massive vote of approval from Wall Street analysts. If you want to see some more stocks on the list, go directly to 5 Stocks Receiving a Massive Vote of Approval From Wall S... Full story
Yahoo Finance • 10 months ago
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, December 18, 2023--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 13, 2023, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards cons... Full story
Yahoo Finance • 10 months ago
We're Not Worried About ACADIA Pharmaceuticals' (NASDAQ:ACAD) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery.... Full story
Yahoo Finance • 10 months ago
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
SAN DIEGO, November 27, 2023--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of a Phase 2 study evaluating the efficacy and safety of ACP-204 for the treatment of hallucinations and delusions ass... Full story
Yahoo Finance • 11 months ago
ACADIA Pharmaceuticals (NASDAQ:ACAD) investors are sitting on a loss of 58% if they invested three years ago
If you love investing in stocks you're bound to buy some losers. But the long term shareholders of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have had an unfortunate run in the last three years. So they might be feeling emotional about the... Full story
Yahoo Finance • 11 months ago
BAKER BROS. ADVISORS LP Bolsters Position in BeiGene Ltd
Significant Addition to BeiGene Holdings BAKER BROS. ADVISORS LP (Trades, Portfolio), a prominent investment firm, has recently expanded its investment in BeiGene Ltd (NASDAQ:BGNE) with a substantial acquisition of shares. On November 14,... Full story
Yahoo Finance • 11 months ago
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
- Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise - 3Q23 DAYBUE™ (trofinetide) net product sales of $66.9 million - 3Q23 NUPLAZID® (pimavanserin) net product sales of $144.8 million S... Full story
Yahoo Finance • last year
Billionaire Stan Druckenmiller’s Small-Cap Stock Picks
In this piece, we will take a look at billionaire Stanley Druckenmiller's small-cap stock picks. If you want to skip our introduction to Mr. Druckenmiller and small-cap stocks in general, then head on over to Billionaire Stan Druckenmiller... Full story
Yahoo Finance • last year
Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome
-- Acadia acquired Levo Therapeutics and worldwide rights to ACP-101 in June 2022 -- ACP-101 (intranasal carbetocin) is a selective oxytocin-receptor agonist for the treatment of hyperphagia in Prader-Willi syndrome -- Company recently c... Full story
Yahoo Finance • last year
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
-- Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.1 SAN DIEGO, April 17, 2023--(BUSIN... Full story
Yahoo Finance • 2 years ago
Analysts See Steady Growth For Acadia Pharma's Nuplazid
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) reported a Q4 EPS loss of $(0.26), missing the consensus of $(0.24) and sales of $136.49 million, beating the consensus of $134.07 million. For FY23, the company expects Nuplazid sales of $520-$550... Full story
Yahoo Finance • 2 years ago
Investors in ACADIA Pharmaceuticals (NASDAQ:ACAD) from three years ago are still down 62%, even after 4.1% gain this past week
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been particularly tough on longer term ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders. Regrettably, they have had to... Full story
Yahoo Finance • 2 years ago
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
Company to host conference call and webcast on Wednesday, November 2, 2022, at 4:30 p.m. Eastern Time SAN DIEGO, October 20, 2022--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quart... Full story
Yahoo Finance • 2 years ago
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%. Zacks Investment Research Image Source: Zacks Investment Research The company’s sole marketed drug, Nup... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline – ACAD
NEW YORK, July 01, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. (“Acadia” or the “Company”)(NASDAQ: ACAD) and certain of its officers. The class action, f... Full story
Yahoo Finance • 2 years ago
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
- 1Q22 net sales of $115.5 million, an 8% increase over 1Q21 - Reiterating FY22 net sales guidance of $510 to $560 million - FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2... Full story
Yahoo Finance • 2 years ago
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
SAN DIEGO, May 02, 2022--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee to review the resubmitted s... Full story
